ArticleStem cells international2020
Exosomes from Placenta-Derived Mesenchymal Stem Cells Are Involved in Liver Regeneration in Hepatic Failure Induced by Bile Duct Ligation.
Article in Stem cells international, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 32 citations in OpenAlex.
- Wnt10a exhibit spatiotemporal singularity in the temporal changes of angiogenesis in regenerated pulp-like tissue.Inflammation and regeneration · 2026Article
- Research Progress on Mesenchymal Stem Cells-Derived Small Size Vesicles for the Treatment of Liver Diseases.International journal of nanomedicine · 2026Review
- Mesenchymal Stem Cell-derived Exosomes in the Treatment of End-stage Liver Disease.Current stem cell research & therapy · 2026Review
- From signaling pathways to clinical trials: mesenchymal stem cells as multimodal regenerative architects in liver cirrhosis therapy.Stem cell research & therapy · 2025Review
- Advances in the treatment of liver injury based on mesenchymal stem cell-derived exosomes.Stem cell research & therapy · 2024Review
- Extracellular vesicles in nanomedicine and regenerative medicine: A review over the last decade.Bioactive materials · 2024Review
- Review
- [Research progress of mesenchymal stem cell-derived extracellular vesicles in liver diseases].Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology · 2023Review
- Strategies to improve the therapeutic efficacy of mesenchymal stem cell-derived extracellular vesicle (MSC-EV): a promising cell-free therapy for liver disease.Frontiers in bioengineering and biotechnology · 2023Review
- Current Therapeutic Options and Potential of Mesenchymal Stem Cell Therapy for Alcoholic Liver Disease.Cells · 2022Review
- Effects of Exosomes Derived from Adipose-Derived Mesenchymal Stem Cells on Pyroptosis and Regeneration of Injured Liver.International journal of molecular sciences · 2022Article
- Mesenchymal Stem Cell-Derived Exosomes: A Promising Therapeutic Agent for the Treatment of Liver Diseases.International journal of molecular sciences · 2022Review
- Mesenchymal stromal cells (MSCs) and their exosome in acute liver failure (ALF): a comprehensive review.Stem cell research & therapy · 2022Review
- The therapeutic potential of exosomes derived from different cell sources in liver diseases.American journal of physiology. Gastrointestinal and liver physiology · 2022Review
- Nucleic acids and proteins carried by exosomes from various sources: Potential role in liver diseases.Frontiers in physiology · 2022Review
- Regenerative Potential of Mesenchymal Stem Cells' (MSCs) Secretome for Liver Fibrosis Therapies.International journal of molecular sciences · 2021Review
- Article
- Review
- A paradigm shift in cell-free approach: the emerging role of MSCs-derived exosomes in regenerative medicine.Journal of translational medicine · 2021Review
- Clinical value of lncRNA CCAT1 in serum extracellular vesicles as a potential biomarker for gastric cancer.Oncology letters · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Although the liver has a regenerative capacity, hepatic failure is a severe and irreversible chronic disease. Placenta-derived mesenchymal stem cells (PD-MSCs) have distinctive features, such as recycling of the placenta waste after birth, ease of accessibility, abundant cell numbers, and strong immunosuppressive properties. Previously, we reported that PD-MSCs can regenerate the liver in hepatic failure through antifibrotic and autophagic mechanisms. Many reports have investigated whether exosomes, which are formed by the budding of vesicular bodies and are emitted into the blood, from stem cells have therapeutic potential in various diseases. C-reactive protein (CRP) is produced in hepatocytes and secreted via vessels. Therefore, the objectives of this study were to compare the expression of CRP in exosomes of a hepatic failure rat model (bile duct ligation, BDL) and to evaluate the therapeutic effect by their correlation between CRP and angiogenesis depending on PD-MSC transplantation. The exosomes were analyzed in a BDL rat model with transplantation of PD-MSCs through LC-MS analysis and precipitation solution. The exosomes, CRP, and factors related to these molecules were evaluated and quantified in exosomes as well as investigated by real-time PCR, Western blot, and immunofluorescence (IF)
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.